Biostar Pharmaceuticals, Inc. Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2017-09-30..
Quick ratio
Overview →Financial period ending 2017-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2017-09-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 5.28M USD | Liabilities, Current |
| Cash and equivalents | 364.97K USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 0.00 USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 170.56K USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2017-09-30 | (m) | $5.28M | $364.97K | (m) | $0.00 | $170.56K | (m) |
| 2017-06-30 | (m) | $5.29M | $407.41K | (m) | $0.00 | $167.29K | (m) |
| 2017-03-31 | (m) | $5.31M | $483.86K | (m) | $5.56M | $164.70K | (m) |
| 2016-12-31 | (m) | $5.62M | $173.29K | (m) | $6.74M | $166.56K | (m) |
| 2016-09-30 | (m) | $6.53M | (m) | (m) | $6.09M | $439.60K | (m) |
| 2016-06-30 | (m) | $6.29M | (m) | (m) | $7.75M | $317.26K | (m) |
| 2016-03-31 | (m) | $6.42M | (m) | (m) | $14.71M | $293.44K | (m) |
| 2015-12-31 | (m) | $7.10M | (m) | (m) | $15.81M | $234.66K | (m) |
| 2015-09-30 | (m) | $10.52M | (m) | (m) | $29.19M | $632.09K | (m) |
| 2015-06-30 | (m) | $9.61M | (m) | (m) | $28.93M | $517.86K | (m) |
| 2015-03-31 | (m) | $8.23M | (m) | (m) | $24.62M | $395.51K | (m) |
| 2014-12-31 | (m) | $8.91M | (m) | (m) | $26.96M | $673.99K | (m) |
| 2014-09-30 | (m) | $8.92M | (m) | (m) | $29.37M | $739.46K | (m) |
| 2014-06-30 | (m) | $9.28M | (m) | (m) | $24.67M | $669.78K | (m) |
| 2014-03-31 | (m) | $6.88M | (m) | (m) | $18.99M | $732.88K | (m) |
| 2013-12-31 | (m) | $4.79M | (m) | (m) | $17.97M | $830.31K | (m) |
| 2013-09-30 | (m) | $10.64M | (m) | (m) | $13.08M | $1.21M | (m) |
| 2013-06-30 | (m) | $10.84M | (m) | (m) | $13.48M | $1.74M | (m) |
| 2013-03-31 | (m) | $11.52M | (m) | (m) | $16.51M | $1.41M | (m) |
| 2012-12-31 | (m) | $12.70M | (m) | (m) | $21.85M | $847.13K | (m) |
| 2012-09-30 | (m) | $4.19M | (m) | (m) | $28.82M | $985.27K | (m) |
| 2012-06-30 | (m) | $2.66M | (m) | (m) | $23.58M | $845.12K | (m) |
| 2012-03-31 | (m) | $6.50M | (m) | (m) | $34.47M | $951.45K | (m) |
| 2011-12-31 | (m) | $6.66M | (m) | (m) | $35.03M | $1.37M | (m) |
| 2011-09-30 | (m) | $11.29M | (m) | (m) | $32.47M | $1.81M | (m) |
| 2011-06-30 | (m) | $9.81M | (m) | (m) | $32.59M | $1.67M | (m) |
| 2011-03-31 | (m) | (m) | $15.30M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $7.59M | (m) | (m) | $28.54M | $351.68K | (m) |
| 2010-09-30 | (m) | (m) | $16.55M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $9.66M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $8.58M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.